Add Glucokinase Activator to Target A1c

NCT02405260 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

190

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: TTP399 400 mg
DRUG: TTP399 800 mg
DRUG: Sitagliptin 100 mg
DRUG: Placebo

Sponsor

vTv Therapeutics